Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Oncotelic Therapeutcs Inc (OTLC)

Oncotelic Therapeutcs Inc (OTLC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Oncotelic Therapeutcs Inc 29397 AGOURA ROAD SUITE 107 AGOURA HILLS CA 91301 USA

www.oncotelic.com Employees: 30 P: 650-635-7000

Sector:

Medical

INDUSTRY GROUPING:

Medical - Biomedical

Description:

Mateon is a biopharmaceutical company focused on the modulation of transforming growth factor-beta (TGF-beta) for the treatment of cancer and infectious diseases, including COVID-19. The company's lead development compound, OT-101 (trabedersen), is a single stranded antisense oligonucleotide targeting the TGF-beta2 mRNA. Mateon is conducting a Phase 2/3 clinical trial of OT-101 in patients suffering from COVID-19. In addition, the company has initiated a global Phase 4 clinical trial of ArtiShield(TM) in India, Africa, and Latin America for the treatment of COVID-19, with results expected in the 4Q20. ArtiShieldTM received marketing approval from India.

Key Statistics

Overview:

Market Capitalization, $K 19,190
Enterprise Value, $K 32,170
Shares Outstanding, K 443,178
Float, K 269,364
% Float 60.78%
Short Interest, K 157
Short Float 0.04%
Days to Cover 1.00
Short Volume Ratio 0.18
% of Insider Shareholders 39.22%
% of Institutional Shareholders 0.00%

Financials:

Annual Sales, $ 0 K
Annual Net Income, $ -4,520 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -1,050 K
EBIT, $ -690 K
EBITDA, $ 2,630 K

Growth:

1-Year Return 14.47%
3-Year Return -16.35%
5-Year Return -81.78%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.00 on 11/17/25
Next Earnings Date 04/21/26
Earnings Per Share ttm 0.00
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-12 on 12/28/12

OTLC Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -22.16%
Return-on-Assets % -6.17%
Profit Margin % 0.00%
Debt/Equity 1.72
Price/Sales N/A
Price/Cash Flow 8.20
Price/Book 2.29
Book Value/Share 0.02
Interest Coverage -4.56
60-Month Beta -0.56
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar